MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

Cancer Research

Volumn 62, Issue 21, 2002, Pages 6108-6115

  Jaboin, Jerry ^a   Wild, Jason ^a,c   Hamidi, Habib ^a   Khanna, Chand ^a   Kim, Chong Jai ^b   Robey, Robert ^a   Bates, Susan E ^a   Thiele, Carol J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEIN P21; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; EWING SARCOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RETINOBLASTOMA; RHABDOID TUMOR; RHABDOMYOSARCOMA; SOLID TUMOR; XENOGRAFT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL CYCLE; CHILD; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; MICE; MICE, NUDE; MICE, SCID; PYRIDINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036828101     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Schwab, M., Alitalo, K., Klempnauer, K., Varmus, H., Bishop, J., Gilbert, F., Brodeur, G., Goldstein, M., and Trent, J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature (Lond.), 305: 245-248, 1983.
2. Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., and Dryja, T. P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (Lond.), 323: 643-646, 1986.
3. Pelletier, J., Bruening, W., Li, F. P., Haber, D. A., Glaser, T., and Housman, D. E. WT1 mutations contribute to abnormal genital system development and hereditary Wilms’ tumour. Nature (Lond.), 353: 431-434, 1991.
4. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., deJong, P., Rouleau, G., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (Lond.), 359: 162-165, 1992.
5. Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R., and Naeve, C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res., 53: 5108-5112, 1993.
6. Pandolfi, P. P. Transcriptional therapy for cancer. Oncogene, 20: 3116-3127, 2001.
7. Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., and Lazar, M. A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol., 18: 7185-7191.
8. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature (Lond.), 391: 811-814, 1998.
9. Ferrara, F. F., Fazi, F., Bianchini, A., Padula, F., Gelmetti, V., Minucci, S., Mancini, M., Pelicci, P. G., Lo Coco, F., and Nervi, C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 61: 2-7, 2001.
10. He, L. Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Jr., Rifkind, R. A., Marks, P. A., Richon, V. M., and Pandolfi, P. P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Investig., 108: 1321-1330, 2001.
11. Lee, D. Y., Hayes, J. J., Pruss, D., and Wolffe, A. P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell, 72: 73-84, 1993.
12. Wolffe, A. P., and Guschin, D. Chromatin structural features and targets that regulate transcription. J. Struct. Biol., 129: 102-122, 2000.
13. Bannister, A. J., and Miska, E. A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci., 57: 1184-1192, 2000.
14. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. DNA damage activates p53 through phosphorylation-acetylation cascade. Genes Dev., 12: 2831-2841, 1998.
15. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell, 8: 1243-1254, 2001.
16. Loidl, P., and Grobner, P. Postsynthetic acetylation of histones during the cell cycle: A general function for the displacement of histones during chromatin rearrangements. Nucleic Acids Res., 15: 8351-8366, 1987.
17. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13: 477-483, 2001.
18. Maruta, H., Greer, K., and Rosenbaum, J. L. The acetylation of α-tubulin and its relationship to the assembly and disassembly of microtubules. J. Cell Biol., 103: 571-579, 2001.
19. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem., 8: 1505-1511, 2001.
20. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem., 42: 65-82, 1982.
21. Glick, R. D., Swendeman, S., Coffey, D. C., Rifkind, R., Marks, P. A., and Richon, V. M. LaQuaglia Hybrid polar histone deacetylase inhibitor induces apoptosis and CD96/CD95 ligand expression in human neuroblastoma. Cancer Res., 17: 4392-4399, 1999.
22. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999.
23. Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., and La Quaglia, M. P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res., 61: 3591-3594, 2001.
24. Thiele, C. J., Reynolds, C. P., and Israel, M. A. Decreased expression of N-myc precedes retinoic acid induced morphological differentiation of human neuroblastoma. Nature (Lond.), 313: 404-406, 1985.
25. Thiele, C. J. Neuroblastoma. In: J. Masters (ed.), Human Cell Culture, Vol. 1, pp. 21-53. Lancaster, United Kingdom: Kluwer Academic Publishers, 1999.
26. Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N. J., and Helman, L. J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res., 52: 2243-2247, 1992.
27. van Valen, F. Ewing’s sarcoma family of tumors. In: J. Masters (ed.), Human Cell Culture, Vol. 1, pp. 55-85. Lancaster. United Kingdom: Kluwer Academic Publishers, 1999.
28. Khanna, C., Jaboin, J., Drakes, E., Tsokos, M., and Thiele, C. J. Characterization of five orthotopic xenograft model of neuroblastoma: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo, 16: 77-85, 2002.
29. 1 checkpoint after γ-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression. J. Biol. Chem., 274: 13118-13126, 1999.
30. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA, 97: 10014-10019, 2000.
31. Hahm, K. B., Cho, K., Lee, C., Im, Y. H., Chang, J., Choi, S. G., Sorensen, P. H., Thiele, C. J., and Kim, S. J. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWING’S SARCOMA-FLII oncoprotein. Nat. Genet., 23: 222-227, 1999.
32. McCune, B. K., Patterson, K., Chandra, R. S., Kapur, S., Sporn, M. B., and Tsokos, M. Expression of transforming growth factor β isoforms in small round cell tumors of childhood. An immunohistochemical study. Am. J. Pathol., 142: 49-58, 1993.
33. Brodeur, G., Seeger, R., and Schwab, M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (Wash. DC), 224: 1121-1124, 1984.
34. Miller, R. G., Jr. Simultaneous statistical inference, Ed. 2. New York: Springer Verlag, 1981.
35. Lee, B. I., Park, S. H., Kim, J. W., Sausville, E. A., Kim, H. T., Nakanishi, O., Trepel, J. B., and Kim, S-J. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells. Cancer Res., 61: 931-934, 2001.
36. Peverali, F. A., Orioli, D., Tonon, L., Ciana, P., Bunone, G., Negri, M., and Della-Valle, G. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions. Oncogene, 12: 457-462, 1996.
37. Schmidt, M. L., Salwen, H. R., Manohar, C. F., Ikegaki, N., and Cohn, S. L. The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ., 5: 171-178, 1994.
38. Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J. M., Nusgens, B. V., and Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21: 427-436, 2002.
39. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S., Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med., 7: 437-443, 2001.